Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients
Background/Aims: In a randomized controlled clinical trial in kidney transplant recipients (NCT01377467) we have recently shown that RANKL inhibition with denosumab significantly improved areal bone mineral density (aBMD) when given during the first year after transplantation. The effect of denosuma...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-09-01
|
| Series: | Kidney & Blood Pressure Research |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/447930 |
| _version_ | 1818505072733061120 |
|---|---|
| author | Marco Bonani Ursina Meyer Diana Frey Nicole Graf Heike A. Bischoff-Ferrari Rudolf P. Wüthrich |
| author_facet | Marco Bonani Ursina Meyer Diana Frey Nicole Graf Heike A. Bischoff-Ferrari Rudolf P. Wüthrich |
| author_sort | Marco Bonani |
| collection | DOAJ |
| description | Background/Aims: In a randomized controlled clinical trial in kidney transplant recipients (NCT01377467) we have recently shown that RANKL inhibition with denosumab significantly improved areal bone mineral density (aBMD) when given during the first year after transplantation. The effect of denosumab on skeletal microstructure and bone strength in kidney transplant recipients is not known. Methods: The purpose of the present bone microarchitecture ancillary study was to investigate high-resolution peripheral quantitative computed tomography (HRpQCT) data from the distal tibia and distal radius in 24 study patients that had been randomized to receive either two injections of denosumab 60 mg at baseline and after 6 months (n=10) or no treatment (n=14). Results: Consistent with the full trial findings, denosumab reduced biomarkers of bone turnover, and significantly increased aBMD at the lumbar spine (median difference of 4.7%; 95% confidence interval [CI] 2.6 - 7.8; pConclusions: These findings demonstrate that denosumab improves bone density and bone quality in first-year kidney transplant recipients at risk to develop osteoporosis. |
| first_indexed | 2024-12-10T21:45:46Z |
| format | Article |
| id | doaj.art-7d40d64e2a074207bac5b398bfe3c09c |
| institution | Directory Open Access Journal |
| issn | 1420-4096 1423-0143 |
| language | English |
| last_indexed | 2024-12-10T21:45:46Z |
| publishDate | 2016-09-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney & Blood Pressure Research |
| spelling | doaj.art-7d40d64e2a074207bac5b398bfe3c09c2022-12-22T01:32:23ZengKarger PublishersKidney & Blood Pressure Research1420-40961423-01432016-09-0141561462210.1159/000447930447930Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant RecipientsMarco BonaniUrsina MeyerDiana FreyNicole GrafHeike A. Bischoff-FerrariRudolf P. WüthrichBackground/Aims: In a randomized controlled clinical trial in kidney transplant recipients (NCT01377467) we have recently shown that RANKL inhibition with denosumab significantly improved areal bone mineral density (aBMD) when given during the first year after transplantation. The effect of denosumab on skeletal microstructure and bone strength in kidney transplant recipients is not known. Methods: The purpose of the present bone microarchitecture ancillary study was to investigate high-resolution peripheral quantitative computed tomography (HRpQCT) data from the distal tibia and distal radius in 24 study patients that had been randomized to receive either two injections of denosumab 60 mg at baseline and after 6 months (n=10) or no treatment (n=14). Results: Consistent with the full trial findings, denosumab reduced biomarkers of bone turnover, and significantly increased aBMD at the lumbar spine (median difference of 4.7%; 95% confidence interval [CI] 2.6 - 7.8; pConclusions: These findings demonstrate that denosumab improves bone density and bone quality in first-year kidney transplant recipients at risk to develop osteoporosis.http://www.karger.com/Article/FullText/447930Dual energy X-ray absorptiometry (DXA)DenosumabHigh-resolution peripheral quantitative computed tomography (HRpQCT)Kidney transplantationOsteoporosis |
| spellingShingle | Marco Bonani Ursina Meyer Diana Frey Nicole Graf Heike A. Bischoff-Ferrari Rudolf P. Wüthrich Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients Kidney & Blood Pressure Research Dual energy X-ray absorptiometry (DXA) Denosumab High-resolution peripheral quantitative computed tomography (HRpQCT) Kidney transplantation Osteoporosis |
| title | Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients |
| title_full | Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients |
| title_fullStr | Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients |
| title_full_unstemmed | Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients |
| title_short | Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients |
| title_sort | effect of denosumab on peripheral compartmental bone density microarchitecture and estimated bone strength in de novo kidney transplant recipients |
| topic | Dual energy X-ray absorptiometry (DXA) Denosumab High-resolution peripheral quantitative computed tomography (HRpQCT) Kidney transplantation Osteoporosis |
| url | http://www.karger.com/Article/FullText/447930 |
| work_keys_str_mv | AT marcobonani effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients AT ursinameyer effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients AT dianafrey effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients AT nicolegraf effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients AT heikeabischoffferrari effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients AT rudolfpwuthrich effectofdenosumabonperipheralcompartmentalbonedensitymicroarchitectureandestimatedbonestrengthindenovokidneytransplantrecipients |